

# ALLERGAN PLC

ISIN: IE00BY9D5467 WKN: G0177J108 Asset Class: **Stock**

## Company



2020/05/08 22:10:00

Price  
**193.02**  
USD

Difference 0.02%(0.03)

Chart  
not available

## Contact Details

ALLERGAN PLC  
Daphne Karydas  
Clonshaugh Business and  
Technology Park  
- Dublin, D17 E400, Ireland

Tel: +1-862-261-7000  
Fax: -  
Web:  
<http://www.allergan.com>  
E-mail: -

## Company Profile

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model -- Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world. Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures              | 2019           |                        | 2018            |                        | 2017            |                        |
|--------------------------------|----------------|------------------------|-----------------|------------------------|-----------------|------------------------|
|                                | Assets         | Liabilities and equity | Assets          | Liabilities and equity | Assets          | Liabilities and equity |
| Current assets                 | 11,126,700,000 |                        | 6,475,400,000   |                        | 11,376,700,000  |                        |
| Common stock capital           |                | 0                      |                 | 0                      |                 | 0                      |
| Fixed assets                   | -              |                        | -               |                        | -               |                        |
| Equity capital of a company    |                | 58,196,400,000         |                 | 65,131,000,000         |                 | 73,837,100,000         |
| Cash and cash equivalents      | 2,503,300,000  |                        | 880,400,000     |                        | 1,817,200,000   |                        |
| Accrued liabilities            |                | -                      |                 | -                      |                 | -                      |
| Other assets                   | 930,100,000    |                        | 2,852,800,000   |                        | 349,500,000     |                        |
| Current liabilities            |                | 11,070,700,000         |                 | 5,727,900,000          |                 | 9,848,100,000          |
| Prepayments and accrued income | -              |                        | -               |                        | -               |                        |
| Non-current liabilities        |                | -                      |                 | -                      |                 | -                      |
| Different income               |                | -                      |                 | -                      |                 | -                      |
| Other liabilities              |                | -                      |                 | -                      |                 | -                      |
| Total assets                   | 94,699,100,000 | 94,699,100,000         | 101,787,600,000 | 101,787,600,000        | 118,341,900,000 | 118,341,900,000        |

## Balance notes

| Accounting standard | 2019    | 2018    | 2017    |
|---------------------|---------|---------|---------|
|                     | US-GAAP | US-GAAP | US-GAAP |
| Employees           | 17,400  | 16,900  | 17,800  |
| Equity ratio        | 61.48%  | 64.00%  | 62.41%  |
| Debt-equity ratio   | 62.66%  | 56.24%  | 60.24%  |

## Others

| Tax Expense Rate | 2019   | 2018   | 2017   |
|------------------|--------|--------|--------|
|                  | -2.86% | 25.82% | 64.22% |

# ALLERGAN PLC

ISIN: IE00BY9D5467 WKN: G0177J108 Asset Class: **Stock**

## Income statement

|  | 2019           | 2018           | 2017            |
|--|----------------|----------------|-----------------|
| <b>Turnover</b>  | 16,088,900,000 | 15,787,400,000 | 15,940,700,000  |
| <b>Net income</b>  | -5,271,000,000 | -5,096,400,000 | -4,125,500,000  |
| <b>EBIT</b>  | -3,922,712,500 | -5,325,910,100 | -8,319,706,500  |
| <b>Operating income before taxes</b>                                 | -5,118,700,000 | -6,856,900,000 | -10,386,400,000 |
| <b>Cash Flow</b>   | 7,238,700,000  | 5,640,100,000  | 5,873,400,000   |
| <b>Net interest income</b>   | -706,200,000   | -866,000,000   | -1,027,900,000  |
| <b>Research and development expenses</b>                             | 1,812,000,000  | 2,266,200,000  | 2,100,100,000   |
| <b>Income taxes</b>  | 146,400,000    | -1,770,700,000 | -6,670,400,000  |
| <b>Result from investments in subsidiaries, associates and other</b> | -              | -              | -               |
| <b>Revenues per employee</b>   | 822,013        | 830,473        | 796,139         |

## Board of Directors

|                               |                               |
|-------------------------------|-------------------------------|
| Brenton L. Saunders           | Chairman of Supervisory Board |
| Adriane M. Brown              | Member of Supervisory Board   |
| Carol Anthony (John) Davidson | Member of Supervisory Board   |
| Christopher J. Coughlin       | Member of Supervisory Board   |
| Christopher W. Bodine         | Member of Supervisory Board   |
| Joseph H. Bocuzzi             | Member of Supervisory Board   |
| Michael E. Greenberg          | Member of Supervisory Board   |
| Nesli Basgoz                  | Member of Supervisory Board   |
| Peter J. McDonnell            | Member of Supervisory Board   |
| Robert J. Hugin               | Member of Supervisory Board   |
| Thomas C. Freyman             | Member of Supervisory Board   |

## Members of Management Board

|                     |                               |
|---------------------|-------------------------------|
| Brenton L. Saunders | Chairman of Managing Board    |
| C. David Nicholson  | Member of Executive Committee |
| Alex Kelly          | Member of Executive Committee |
| Bill Meury          | Member of Executive Committee |
| Bob Bailey          | Member of Executive Committee |
| Kellie Sears        | Member of Executive Committee |
| Matt Walsh          | Member of Executive Committee |
| Wayne R. Swanton    | Member of Executive Committee |